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N-Alkyl perfluorooctane sulfonamides have been widely used as surfactants on fabrics and papers,
fire retardants, and anticorrosion agents, among many other commercial applications. The broad use,
global distribution, and environmental persistence of these compounds has generated considerable interest
regarding potentially toxic effects. We have previously reported that perfluorooctanesulfonamidoacetate
(FOSAA) and N-ethylperfluorooctanesulfonamidoacetate (N-EtFOSAA) induce the mitochondrial perme-
ability transition (MPT) in vitro, resulting in cytochrome c release, inhibition of respiration, and generation
of reactive oxygen species. By synthesizing the corresponding methyl esters of FOSAA and N-EtFOSAA
(methyl perlfuorinated sulfonamide acetates), we tested the hypothesis that the N-acetate moiety of FOSAA
and N-EtFOSAA is the functional group responsible for induction of the MPT. Swelling of freshly isolated
liver mitochondria from Sprague-Dawley rats was monitored spectrophotometrically and membrane
potential (¢¾) was measured using a tetraphenylphosphonium-selective (TPP+) electrode. In the presence
of calcium, 40 íM FOSAA and 7 íM N-EtFOSAA each induced mitochondrial swelling and a biphasic
depolarization of membrane potential. Mitochondrial swelling and the second-phase depolarization were
inhibited by cyclosporin-A or the catalyst of K+/H+ exchange nigericin, whereas the first-phase
depolarization was not affected by either. In contrast, the methyl esters of FOSAA and N-EtFOSAA
exhibited no depolarizing or MPT inducing activity. Results of this investigation demonstrate that the
carboxylic acid moiety of the N-acetates is the active functional group, which triggers the MPT by
perfluorinated sulfonamides.
Introduction
Since the early 1950s, N-alkyl perfluorooctane sulfonamides,
including N-acetyl-perfluorooctanesufonamide (FOSAA)1 and
N-ethylperfluorooctanesulfonamidoacetate (N-EtFOSAA), have
been widely used as surfactants on fabrics and papers, fire
retardants, anticorrosion agents, and antistatic agents for film
production, among other commercial applications (1). The
perfluorooctane sulfonamides were manufactured for their
chemical and thermal inertness and special surface-active
characteristics. The high-energy fluorine-carbon bonds impart
the physical and chemical stability that renders perfluorooctanes
resistant to hydrolysis, photolysis, microbial degradation, and
metabolism. Consequently, the perfluorooctanes are extremely
persistent in the environment (1, 2).
The broad application, global distribution, and environmental
persistence of these perfluorinated compounds has generated
considerable concern regarding their potential toxicity (3). The
terminal degradation product of most N-alkyl perfluorooctane
sulfonamides is perfluorooctanesulfonate (PFOS). PFOS and
FOSAA have been identified in individual and pooled human
serum samples from the United States general population (4-
6), and it has been shown that FOSAA and N-EtFOSAA are
metabolites in the biotransformation pathway of perfluorinated
sulfonamido alcohols (7). PFOS itself has been detected in birds,
fish, and mammalian tissues from the Canadian Artic, Baltic
and Mediterranean Seas, and the Great Lakes of North America
(1, 8-10). Although the source of PFOS in human blood is not
well-characterized, it may likely involve exposure to PFOS itself
or precursor molecules such as FOSAA and N-EtFOSAA (5).
Because there is much yet to be learned about the distribution
and degradation of perfluorooctane sulfonamides, estimating
environmental exposure to any particular perfluorooctane
including FOSAA and N-EtFOSAA is complicated and inexact.
There have been a number of studies with a variety of
exposure regimens in which a wasting syndrome or cachexia
has been observed in animals exposed to perfluorinated acids.
The most prominent acute and subchronic high-dose effects of
perfluorinated acids in adult rodents and monkeys are altered
lipid metabolism, hepatocellular hypertrophy, and vacuolation,
decreased serum cholesterol, decreased triglycerides, hepatome-
galy, decreased body weight, and death (11-14). PFOS
exposure has also been shown to have adverse developmental
effects in rodents where in vitro exposure results not only in
maternal weight loss but also in increased abortions, reduced
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birth weights, and a profound neonatal morbidity in rats (15-
17). In all of these studies the most prominent toxicological
outcome appears to be a dose-dependent metabolic disruption.
Inhibition of mitochondrial respiration and impairment of
â-oxidation, as a result of uncoupling of oxidative phosphory-
lation or the induction of the mitochondrial permeability
transition (MPT), have been implicated in a variety of patholo-
gies related to disrupted lipid metabolism and hepatotoxicity
(18). This suggests a potential role for mitochondrial dysfunction
in the underlying mechanism of toxicity of the perfluorinated
sulfonamides.
Multiple in vitro studies have shown the perfluorooctane
sulfonamides to disrupt mitochondrial bioenergetics by three
distinct mechanisms: uncoupling mitochondrial respiration,
increasing nonspecific membrane permeability, and induction
of calcium-dependent mitochondrial swelling (19-21). Specif-
ically, FOSAA and N-EtFOSAA have been shown to be potent
inducers of the MPT, which results in the release of cytochrome
c, inhibition of respiration, and the generation of reactive oxygen
species (22). The fact that these effects occur at low micromolar
concentrations further supports the possibility that mitochondrial
dysfunction may be an important factor in the pathogenesis
caused by perfluorooctane sulfonamides.
The mitochondrial permeability transition represents a non-
selective increase in the permeability of the inner mitochondrial
membrane to solutes up to 1.5 kD in size (23). It is characterized
by dependence on matrix Ca2+ and is inhibited by elevated trans-
membrane potential, acidic matrix pH, and the immunosup-
pressant cyclosporin-A (CsA) (24-26). Ca2+ can itself induce
the MPT, but most often the MPT is a result of Ca2+ acting in
conjunction with various “inducing agents” such as fatty acids
or oxidants (27). Associated with MPT induction is the rapid
equilibration of solutes across the mitochondrial membranes
leading to depolarization of membrane potential, osmotic
swelling, inhibition of oxidative phosphorylation, and release
of potential apoptogenic factors, (28) including cytochrome c
(29).
The purpose of the current investigation was to test the
hypothesis that the N-acetate moiety of FOSAA and N-
EtFOSAA is responsible for the induction of the MPT. To test
this hypothesis, we synthesized methyl esters of the acetates
and assessed them along with FOSAA and N-EtFOSAA for
MPT inducing activity by measuring the change in ¢¾ and
mitochondrial swelling in the presence and absence of Ca2+,
nigericin, and/or CsA. The results reported herein add significant
new understanding to the mechanism by which N-acetyl
perfluorooctane sulfonamides induce the MPT and identifies
the N-acetate as the critical functional group responsible for
the activity of these compounds. The compounds chosen for
inclusion in this investigation are depicted in Table 1.
Experimental Procedures
Mitochondrial Isolation. Mitochondria were isolated from liver
of adult mixed-sex Sprague-Dawley rats (175-300 g body weight)
by differential centrifugation (30). Rats were purchased from Harlan
Sprague-Dawley (Madison, WI) and acclimated in an AAALAC-
accredited, climate-controlled animal-care facility for at least 3 days
and fasted for 12-18 h prior to the experiment. Animals were
euthanized in a CO2 chamber followed by decapitation. The liver
was immediately excised, weighed, immersed in 40 mL of isolation
medium (200 mM mannitol, 10 mM sucrose, 5 mM Hepes, 1 mM
EGTA, pH 7.4) and minced with scissors. The mitochondria were
isolated and prepared as previously described (21, 22). The resulting
mitochondrial pellet was re-suspended in a washing medium (200
mM mannitol, 10 mM sucrose, 5 mM Hepes, pH 7.4) to a final
protein concentration of 35-50 mg/mL. Protein concentration was
determined with the Bradford assay using BSA as a standard (31).
Diazomethane Preparation. p-Toluenesulfonylmethylnitrosa-
mide (Diazald, Aldrich Chemical Co., 4.28 g., 2 mmol) in ether
(25 mL) was added slowly through a nonground glass separation
funnel to a solution of potassium hydroxide (1.0 g) in water (2.0
mL) maintained at 65 °C in a nonground glass distillation apparatus
(25 mL). As the reaction proceeded, the diazomethane co-distilled
with ether into a receiving flask containing ether (10 mL). When
all the Diazald was added, additional ether (10 mL) was introduced
and distillation continued until the distillate was colorless. The
resulting yellow solution of diazomethane in ether was used without
further purification.
Ester Preparation. The ethereal solution of diazomethane was
introduced dropwise into a solution of the fluorinated acids
dissolved in ether using a fire-polished disposable pipet. The
addition of diazomethane was continued until no further nitrogen
gas was evolved and the resulting ester solution remained a pale
yellow color. The ether and excess diazomethane was allowed to
evaporate in a hood and the residual esters used without further
purification.
The authors chose the diazomethane esterification method because
of its specificity. This method is a widely used analytical protocol
for synthesizing and quantifying small quantities of highly valuable
carboxylic acids where purity and yield are critical. The U.S. EPA
recognizes diazomethane esterification as a preferred method for
methyl derivatization of organic halo-acid herbicides for GC
quantification (U.S. EPA Method 8151a Revision - 1, 1996).
Urbansky et al. used diazomethane esterification to demonstrate
the quantitation of concentrations of halocarboxylates near the lower
detection limits of gas chromatography with electron capture
detection (GC-ECD) (32, 33). Additionally, because analytical
characterization of the perfluorinated test compounds is exceedingly
Table 1. Structures of the N-Acetylperfluorooctanesulfonamides and
Corresponding Esters
carboxylic acid
R-COOH
+ diazomethane
CH2N2
f methyl ester
R-COO-CH3
+ nitrogen gas
vN2
1306 Chem. Res. Toxicol., Vol. 19, No. 10, 2006 O’Brien et al.
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challenging and cost-prohibitive, we chose the method in which
we could have the highest confidence in the purity and yield of the
product.
Mitochondrial Swelling. Changes in mitochondrial volume were
estimated by changes in light scattering as monitored spectropho-
tometrically at 540 nm (21, 34). Freshly isolated mitochondria were
suspended at 0.5 mg/mL in 175 mM sucrose, 5 mM Hepes, 50
mM KCl, 2.5 mM KH2PO4, and 10 íM EGTA (pH 7.4) supple-
mented with 2 íM rotenone and 1 íg/mL oligomycin. The reaction
was stirred continuously at 30 °C for 20 min. The mitochondria
were energized with 5 mM succinate for 2 min before adding 25
íM CaCl2. FOSAA, N-EtFOSAA, FOSAA methyl ester, or
N-EtFOSAA methyl ester was added 2 min later. Where indicated,
2 íM of the MPT inhibitor cyclosporin A (CsA) (24) was added
just prior to succinate, or 200 nM nigericin, a catalyst of K+/H+
exchange, was added just prior to the test compound. The criteria
for establishing induction of the MPT was a decrease in light
scattering of at least 0.5 absorbance units 6 min postaddition of
test compound, which was inhibited completely by 2 íM CsA.
O’Brien and Wallace previously established the concentrations of
FOSAA and N-EtFOSAA used in this study (22). The phase
partitioning properties of the perfluorinated octanes suggest that
these compounds do not partition to the aqueous or organic phase,
but rather to a separate phase altogether (1). However, in vivo, the
perfluorinated octanes with poor aqueous solubility, including
n-ethyl perfluoroctanesulfonamido ethyl alcohol, tend to partition
to the proteins in the serum and liver (35). With solubility in mind
the concentration of the methyl esters of FOSAA and N-EtFOSAA
tested were 10 times that of the corresponding acetates, and all
experiments were run in a continuously mixed reaction chamber
at 30° to maximize ester partitioning to the mitochondrial fraction
of the reaction.
TPP+ Methods. A TPP+ selective electrode was prepared as
described by (36). Changes in membrane potential (¢¾) of rat liver
mitochondria were measured by a tetraphenylphosphonium ion
(TPP+) sensitive electrode. Briefly, 0.5 mg of protein/mL was
incubated at 30 °C in a buffered solution of 175 mM sucrose, 50
mM KCl, 10 mM MOPS, 1 mM KH2PO4, and 10 íM EGTA in
the presence of 2 íM TPP+, and supplemented with 2 íM rotenone
and 1 íg/mL oligomycin. The reaction was stirred continuously at
30 °C during the incubation. The mitochondria were energized with
5 mM succinate for 1.5 min before adding 25 íM CaCl2. FOSAA,
N-EtFOSAA, FOSAA methyl ester, N-EtFOSAA methyl ester, or
a DMSO control was added 2 min later. Where indicated, 2 íM of
the MPT inhibitor cyclosporin A (CsA) or 200 nM nigericin was
added just prior to the test compound. As reported, phase 1
depolarization describes the change in ¢¾ immediately upon
addition of the test compound, and phase 2 depolarization describes
the change in ¢¾ 6 min following the addition of the test
compound. Results were reported in millivolts (mV), which were
calculated as described (36-38). Through initial optimization we
determined that 2 íM TPP+ provided the most sensitive and
responsive measure of ¢¾ for this study.
Reagents. All fluorochemical compounds were synthesized,
characterized, and provided gratis by the 3M Company, St. Paul,
MN. The methyl esters of the fluorochemical acetates were
synthesized in house. Cyclosporin A was provided as a generous
gift of Sandoz Pharmaceuticals (East Hanover, NJ, www.san-
doz.com), Ultra Pure sucrose was purchased from ICN Biomedicals,
Inc. (Aurora, OH, www.icnbiomed.com), and all other reagents were
from Sigma-Aldrich (St. Louis, MO, www.sigma-aldrich.com).
Hazardous Materials. Caution: Diazald is a seVere skin irritant
and all skin contact should be aVoided. Diazomethane is extremely
toxic, is an irritant, and has been cited as a carcinogen (39-41).
Diazomethane has been known to explode unaccountably both as
a gas and in solution. Rough surfaces are proVen initiators of
detonation (41). Extreme caution should be used when handling
both.
Statistical Analysis. All experiments were repeated using freshly
isolated hepatic mitochondria from at least three separate animals
with a randomized selection of sexes. The results were analyzed
by 2-way ANOVA and Tukey’s post-hoc test. A probability of (p
< 0.05) was used as the criterion for statistical significance.
Results
Calcium Titration. Ca2+ is electrophoretically accumulated
by mitochondria up to 1 ímol/mg of protein via the near 200
mV electronegative trans-membrane potential (42). However,
there is a finite capacity which, if exceeded, triggers the
mitochondria to undergo the induction of the mitochondrial
permeability transition (MPT) (23, 43). In order to quantify
calcium-loading capacity, which is considered to be a sensitive
and specific indicator of mitochondrial competence and sensitiv-
ity to induction of the MPT (21), mitochondria were titrated
with concentrations of calcium ranging from 0 to 100 nmol/mg
of protein. Figure 1 is a representative tracing of a routine
calcium titration. From this we established on average a
concentration of 25 íM calcium (50 nmol/mg of protein) as an
amount that is below the calcium loading capacity of control
mitochondria, yet sufficient to support induction of the MPT
in response to selected inducing agents.
Mitochondrial Membrane Potential (¢¾). Figures 2 and
3 illustrate a typical experiment for measuring the effects of
the N-acetyl perfluorooctane sulfonamides (FOSAA and N-
EtFOSAA, respectively) and the corresponding methyl esters
on mitochondrial trans-membrane potential in the presence and
absence of Ca2+, nigericin, and CsA. The results indicate that
there are two phases of depolarization that occur upon addition
of FOSAA and N-EtFOSAA. The initial, partial depolarization
occurs immediately upon addition of 40 íM FOSAA or 7 íM
N-EtFOSAA (Figures 2 and 3; panels B, C, D, and E) where
there is approximately a (+) (15-25) mV change in ¢¾. This
event occurs in the presence or absence of Ca2+, nigericin, or
CsA. In direct contrast, upon addition of the corresponding
methyl esters of the acetates (Figures 2 and 3; panel F), there
is no change in ¢¾. Even at 10 times the concentration of the
acetates, the esters still do not initiate depolarization or induce
the MPT. The results of the initial depolarization for FOSAA,
N-EtFOSAA in the presence and absence of Ca2+, nigericin,
and CsA, and the corresponding methyl esters are presented
quantitatively in Figure 4, phase 1 depolarization. The initial
depolarization induced by the DMSO control and the esterified
treatments is significantly less than that of the FOSAA or
N-EtFOSAA treatments in both cases.
The slower phase of depolarization is reported as the change
in ¢¾ 6 min after the addition of the test compound. In Figures
2 and 3, panel B illustrates the change in ¢¾ by FOSAA and
N-EtFOSAA in the presence of Ca2+ absent nigericin and CsA.
Figure 1. Calcium titration to measure permeability transition
threshold. Swelling of rat liver mitochondria was monitored by light
scattering at 540 nm. (0.5 mg of protein/mL) were incubated at 30 °C
in a buffered solution of 175 mM sucrose, 50 mM KCl, 10 mM MOPS,
1 mM KH2PO4, 10 íM EGTA in the presence of 2 íM rotenone, 5
mM succinate, 1 íg/mL oligomycin, plus 0, 20, 30, 40, and 50 íM
Ca2+, and 50 íM Ca2+ plus cyclosporin A.
Inhibition of Perfluoroalkyl Sulfonamide MPT Chem. Res. Toxicol., Vol. 19, No. 10, 2006 1307
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This secondary depolarization does not occur in the absence of
Ca2+ (Figures 2 and 3; panel D) and is inhibited in the presence
of either CsA or nigericin (Figures 2 and 3; panels C and E,
respectively). There is no occurrence of membrane depolariza-
tion in the presence of the DMSO control or the methyl esters
of the acetates (Figures 2 and 3; panel F). The results of the
secondary depolarization for FOSAA, N-EtFOSAA in the
presence and absence of Ca2+, nigericin and CsA, and the
corresponding methyl esters are presented quantitatively in
Figure 4, phase 2 depolarization. The secondary depolarization
induced by the FOSAA or N-EtFOSAA + Ca2+ in both cases
is significantly greater than that of the DMSO control. In all
cases the absence of Ca2+, the presence of nigericin, CsA, or
the methyl esters of FOSAA and N-EtFOSAA significantly
inhibited phase 2 depolarization caused by FOSAA and N-
EtFOSAA plus Ca2+.
Mitochondrial Swelling. Calcium-dependent, CsA-inhibited
mitochondrial swelling measured by light scattering at 540 nM
is a characteristic measure of MPT induction (25, 26). To verify
that the observed membrane depolarization is related to the MPT
induction, we recorded light scattering under the same treatment
conditions as the membrane potential measurements. Figure 5
illustrates the typical experimental run for testing the effects of
the N-acetyl perfluorooctane sulfonamides (FOSAA and N-
EtFOSAA) and the corresponding methyl ester test compounds
on mitochondrial light scattering at 540 nM in the presence and
absence of nigericin or CsA. Figure 5, panels A and B, show
that 40 íM FOSAA or 7 íM N-EtFOSAA induced mitochon-
drial swelling, both of which are inhibited by CsA. In contrast,
400 íM FOSAA methyl ester (Figure 5; panel A) and 70 íM
N-EtFOSAA methyl ester do not induce mitochondrial swelling
(Figure 5; panel B). Figure 5 panel C depicts nigericin inhibition
of mitochondrial swelling. Two hundred nanomolar nigericin
in a buffer containing 51 mM K+ protects against mitochondrial
swelling induced by FOSAA and N-EtFOSAA. In all cases there
is a delay from the time of test compound addition until the
initiation of mitochondrial swelling.
The results of mitochondrial swelling induced by FOSAA,
N-EtFOSAA in the presence of Ca2+, plus or minus nigericin
or CsA, and the corresponding methyl esters are presented
quantitatively in Figure 5, panel D. In each case there is a
significant decrease in light scattering by FOSAA and N-
EtFOSAA versus control, whereas the absence of Ca2+ or in
the presence of nigericin or CsA protects against mitochondrial
Figure 2. Membrane potential (¢¾) of rat liver mitochondria was
measured by a tetraphenylphosphonium ion (TPP+) sensitive electrode.
Results reported in millivolts (mV). 0.5 mg of protein/mL were
incubated at 30 °C in a buffered solution of 175 mM sucrose, 50 mM
KCl, 10 mM MOPS, 1 mM KH2PO4, 10 íM EGTA in the presence of
2 íM TPP+, 2 íM rotenone, 5 mM succinate, and 1 íg/mL
oligomycin: (A) 25 íM Ca2+, DMSO control (carrier); (B) 25 íM
Ca2+, 40 íM FOSAA; (C) 25 íM Ca2+, 40 íM FOSAA, plus 2 íM
cyclosporin A; (D) 40 íM FOSAA absent of Ca2+; (E) 25 íM Ca2+,
40 íM FOSAA, plus 200 nM nigericin; and (F) 25 íM Ca2+, 400 íM
FOSAA ester. Traces are representative of 3-5 repetitions, each using
separate mitochondrial preparations.
Figure 3. Membrane potential (¢¾) of rat liver mitochondria was
measured by a tetraphenylphosphonium ion (TPP+) sensitive electrode.
Results reported in millivolts (mV). 0.5 mg of protein/mL were
incubated at 30 °C in a buffered solution of 175 mM sucrose, 50 mM
KCl, 10 mM MOPS, 1 mM KH2PO4, 10 íM EGTA in the presence of
2 íM TPP+, 2 íM rotenone, 5 mM succinate, and 1 íg/mL
oligomycin: (A) 25 íM Ca2+, DMSO control (carrier); (B) 25 íM
Ca2+, 7 íM N-EtFOSAA; (C) 25 íM Ca2+, 7 íM N-EtFOSAA, plus 2
íM cyclosporin A; (D) 7 íM N-EtFOSAA absent Ca2+; (E) 25 íM
Ca2+, 7 íM N-EtFOSAA, plus 200 nM nigericin; and (F) 25 íM Ca2+,
70 íM N-EtFOSAA ester. Traces are representative of 3-5 repetitions,
each using separate mitochondrial preparations.
1308 Chem. Res. Toxicol., Vol. 19, No. 10, 2006 O’Brien et al.
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swelling. The change in light scattering caused by the methyl
esters was significantly less than that induced by FOSAA and
N-EtFOSAA plus Ca2+. This data indicates that swelling is
directly related to induction of the MPT by the N-acetyl
perfluorooctane sulfonamides and that the N-acetate of FOSAA
and N-EtFOSAA is the critical functional group responsible for
the activity of these compounds.
Discussion
The results of this investigation demonstrate that induction
of the MPT by the N-acetyl perfluorooctane sulfonamides,
FOSAA and N-EtFOSAA, is an event that is entirely dependent
upon the carboxylic acid functional group. Induction of the MPT
is preceded by a partial (15-25 mV) depolarization of ¢¾ that
occurs immediately upon addition of the N-acetyl test com-
pounds (Figures 4; phase 1 depolarization). This initial depo-
larization occurs in the absence of Ca2+ and in the presence of
cyclosporin-A, indicating that it is not a result of MPT induction.
The fact that the initial depolarization is completely blocked
by methyl-esterification of the acids, but not by nigericin, is
evidence that the effect requires the carboxyl moiety and appears
to be the result of an immediate translocation of charge across
the inner mitochondrial membrane. This electrophoretic inter-
pretation of the TPP+ data is supported by the fact that in the
presence of CsA there is no swelling (Figure 5), whereas
nonspecific swelling would be expected if the initial depolar-
ization were the result of generalized membrane dissolution by
the perfluorinated sulfonamides.
The second component of membrane depolarization is the
gradual and complete collapse of ¢¾ (Figures 2 and 3, panel
B). This secondary phase requires Ca2+ and is inhibited by CsA
or nigericin, indicating that it is a consequence of MPT
induction. The secondary-phase depolarization does not occur
with the corresponding methyl esters of the acetates, providing
further evidence that mitochondrial membrane depolarization
and induction of the MPT are entirely dependent upon the
presence of the carboxylic acid.
The methyl esters of the acetates used in this investigation
do not induce mitochondrial swelling (Figure 5A,B), nor do
they cause membrane depolarization as is observed with FOSAA
and N-EtFOSAA. Membrane integrity and membrane potential
are not compromised in the presence of the esters; therefore,
general membrane solubility of the perfluorinated compounds
is likely not the disruptive mechanism observed in this
investigation. These findings are in agreement with those of
Starkov and Wallace who found that the perfluorinated com-
pounds without amide or acidic moieties do not disrupt
mitochondrial bioenergetics (21). Under every treatment condi-
tion involving FOSAA and N-EtFOSAA the initial depolariza-
tion occurs immediately upon addition, yet only in the presence
of Ca2+ does the secondary depolarization occur. This evidence
suggests a specific interaction with mitochondrial targets leading
to an immediate depolarization of membrane potential, which
does not occur in the absence of the carboxylic acid moiety.
The relationship between mitochondrial depolarization and
MPT induction has been the subject of many studies. It has
been demonstrated that at low membrane potential mitochondrial
redox potential is decreased because NAD(P)H transhydrogenase
cannot sustain adequate NADPH and GSH levels (44), which
may result in MPT induction. In fact, Castilho et al. proposed
that a decrease in ¢¾ results in Ca2+-induced ROS accumula-
tion, thiol cross-linking, and MPT induction (45). Others
advocate that the MPT is voltage-sensitive and a decrease in
¢¾ results in a greater likelihood of MPT induction (25, 46).
Regardless of the initiating mechanism, the final outcome of
MPT induction is a complete collapse of the ¢¾ and,
consequently, the electrochemical proton gradient (47).
There have been a multitude of studies regarding the
mechanism by which fatty acids induce the MPT. It has been
reported that fatty acid induced MPT is a result of proton
translocation across the inner mitochondrial membrane which
lowers ¢¾ to a MPT gating potential (27, 48). Once the gating
potential is achieved, MPT induction is more likely. Other
proposed mechanisms include the cycling of monovalent cations
other than protons caused by fatty acid membrane translocation,
again resulting in an electrogenic triggering of mitochondrial
swelling (49). These mechanisms appear to require the ionized
fatty acid be shuttled back to the inner membrane space through
a process that apparently involves transporters such as the
adenine nucleotide translocator (ANT) (50) or dicarboxylate
carrier (51, 52). Regardless of the specific target, each proposed
mechanism has in common a process by which fatty acids “flip-
flop” back and forth across the inner mitochondrial membrane
and cause a dissipation of ¢¾. Although the perfluorinated
carbon tail of FOSAA and N-EtFOSAA imparts a more rigid
physical character to the molecule, the aliphatic head of the
sulfonamide will have properties comparable to non-fluorinated
fatty acids. It is possible that the N-acetyl perfluorinated
sulfonamides interact with the inner mitochondrial membrane
in a fashion similar to non-fluorinated fatty acids.
The findings of this investigation allow us to propose that
the initial depolarization of mitochondrial ¢¾ is an electro-
phoretic event caused by the N-acetyl perfluorooctane sulfona-
mides translocating charge, most likely protons, across the
mitochondrial membranes. The specific mechanism of the
observed charge translocation is not completely clear. It may
Figure 4. F (FOSAA) and N-Et (N-EtFOSAA) induced change in
membrane potential (¢¾) as measured by a (TPP+) sensitive electrode.
Results reported in millivolts (mV). Phase 1 depolarization is the
immediate change in ¢¾ upon addition of the test compound. Phase
2 depolarization is the change in ¢¾ 6 min after the addition of the
test compound. The concentrations and additions are as reported in
Figures 2 and 3. Bars represent the mean ( S.E.M. of 3-5 repetitions
each analyzed by 2-way ANOVA and Tukey’s post-hoc test. A
probability of (p < 0.05) was used as the criterion for statistical
significance. (/) Statistically significant difference compared to treatment
alone.
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be the result of a rearrangement of membrane phospholipids,
which induces a generalized proton leak, or it could be due to
direct protonophoric activity of FOSAA and N-EtFOSAA.
Calculated pKa values of less than 5 for the test compounds
would support the first interpretation, but the fact that the esters
do not induce phase 1 depolarization, or that there is no
mitochondrial swelling induced by FOSAA or N-EtFOSAA in
the presence of CsA, supports the protonophoric interpretation.
In either case, as a consequence of phase 1 depolarization, ¢¾
is depressed, causing the mitochondria to become more sus-
ceptible to MPT induction. The hyperpolarization and matrix
acidification induced by the presence of nigericin (25, 53), which
inhibits the MPT, also supports this interpretation. The secondary
membrane depolarization observed is specifically a consequence
of MPT induction. The results also provide insight as to why
the fully substituted sulfonamide N-EtFOSAA is approximately
5 times more potent than the secondary substituted sulfonamide
FOSAA. It is estimated that the pKa of the proton on the
secondary substituted sulfonamide is quite low due to its
proximity to the strong electron-withdrawing effects of fluorine,
and therefore, the secondary amide of FOSAA would be present
in its anionic state under the conditions of these experiments.
This anionic state would render FOSAA less soluble in the
mitochondrial membranes, whereas the fully substituted sul-
fonamide N-EtFOSAA does not have that anionic site and
therefore is suspected to be much more membrane-soluble.
In conclusion, the fact that the pathologies expressed in vivo
resulting from exposure to perfluorinated acids in rodents and
monkeys are altered lipid metabolism, hepatocellular hypertro-
phy and vacuolation, decreased serum cholesterol, decreased
triglycerides, hepatomegaly, and decreased body weight with
no obvious histopathology provides strong evidence that these
events are metabolic in nature. PFOS has generated considerable
interest because of its environmental penetrance and persistence.
It has been detected in a variety of species of wildlife worldwide
with mean liver concentrations as high as 1.7 ppm in predators
such as polar bears (9). Exposure of the general human
population is demonstrated by the detection of PFOS in banked
serum at concentrations of 0.03-0.175 ppm (4, 6, 54) with
occupational exposures of fluorochemical production workers
reported at 0.04-12.70 ppm serum PFOS (55). Since PFOS
has been suggested to be the terminal metabolite of the N-alkyl-
perfluorooctanesulfonamides in vivo (3, 14, 17), the detection
of PFOS in human or environmental monitoring studies may
reflect either direct exposure to PFOS itself or exposures to more
complex structural analogs. The concentrations used in this study
are higher than those currently observed in animal or human
serum samples (FOSAA, approximately 22 ppm, and N-
EtFOSAA, approximately 3.2 ppm compared to the PFOS
concentration of 12 ppm in humans). However, the in vivo
partitioning of the perfluorinated sulfonamides to proteins in
the liver and serum, and the fact that FOSAA and N-EtFOSAA
induce acute in vitro outcomes resulting in a distinct disruption
of mitochondrial bioenergetics that may be related to the general
metabolic disruption observed in vivo, supports the relevance
of the concentrations applied. More importantly, the concentra-
Figure 5. Swelling of rat liver mitochondria was monitored by light scattering at 540 nm. (0.5 mg of protein/mL) were incubated at 30 °C in a
buffered solution of 175 mM sucrose, 50 mM KCl, 10 mM MOPS, 1 mM KH2PO4, 10 íM EGTA in the presence of 2 íM rotenone, 5 mM
succinate, 1 íg/mL oligomycin, 25 íM Ca2+ plus the selected perfluorinated compound or DMSO (carrier) at the indicated concentration in the
presence and absence of 2 íM cyclosporin A (CsA). Controls were treated with 25 íM Ca2+. Mitochondrial swelling traces are representative of
3 repetitions, each using separate mitochondrial preparations. (A) 400 íM FOSAA ( cyclosporin A, 400 M FOSAA ester; (B) 7 íM N-Et-FOSAA
( cyclosporin A, 70 íM N-EtFOSAA ester; (C) 7 íM N-EtFOSAA, 40 íM FOSAA in the presence and absence of 200 nM nigericin; (D) F
(FOSAA) and N-Et (N-EtFOSAA) induced decrease in absorbance measured at 540 nM. Results reported as change in arbitrary absorbance units
6 min after the addition of the test compound. Bars represent the mean ( S.E.M. of 3 repetitions each analyzed by 2-way ANOVA and Tukey’s
post-hoc test. A probability of (p < 0.05) was used as the criterion for statistical significance. (/) Statistically significant difference compared to the
treatment.
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tions of PFOS observed in serum and liver of neonates with
high mortality in a PFOS toxicity study (56) exceed the
concentrations of N-EtFOSAA used in this study by more than
10-fold. Finally, identification of the carboxylic acid moiety as
requisite to initiate the MPT adds significant new understanding
to the process by which N-acetyl perfluorooctane sulfonamides
disrupt mitochondrial bioenergetics and supports the hypothesis
that this disruption plays a significant role in the observed
pathological outcomes in vivo.
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